Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
Sign Up
Log in
Bukwang Pharm Co Ltd banner

Bukwang Pharm Co Ltd
KRX:003000

Watchlist Manager
Bukwang Pharm Co Ltd Logo
Bukwang Pharm Co Ltd
KRX:003000
Watchlist
Price: 7 660 KRW 6.83% Market Closed
Market Cap: ₩755.7B
Write Note Create Alert Ask AI

Bukwang Pharm Co Ltd's latest stock split occurred on Dec 29, 2020

The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.

Before the split, Bukwang Pharm Co Ltd traded at 29000.0009 per share. Afterward, the share price was about 26796.2264.

The adjusted shares began trading on Dec 29, 2020. This was Bukwang Pharm Co Ltd's 18th stock split, following the previous one in Dec 27, 2019.

Last Splits:
Dec 29, 2020
1-for-1
Dec 27, 2019
1-for-1
Dec 27, 2018
1-for-1
Dec 27, 2017
1-for-1
Dec 28, 2016
1-for-1
Pre-Split Price
25 778.9878 29 000.0009
Post-Split Price
26 796.2264
Before
After
Last Splits:
Dec 29, 2020
1-for-1
Dec 27, 2019
1-for-1
Dec 27, 2018
1-for-1
Dec 27, 2017
1-for-1
Dec 28, 2016
1-for-1

Bukwang Pharm Co Ltd
Stock Splits History

Bukwang Pharm Co Ltd Stock Splits Timeline
Dec 29, 2020
Dec 29, 2020
Split 1-for-1
/1
Pre-Split Price
25 778.9878 29 000.0009
Post-Split Price
26 796.2264
Before
After
Dec 27, 2019
Dec 27, 2019
Split 1-for-1
/1
Pre-Split Price
12 478.8927 14 950.0005
Post-Split Price
12 622.8147
Before
After
Dec 27, 2018
Dec 27, 2018
Split 1-for-1
/1
Pre-Split Price
18 260.8548 28 700.0014
Post-Split Price
20 033.0049
Before
After
Dec 27, 2017
Dec 27, 2017
Split 1-for-1
/1
Pre-Split Price
14 477.9604 25 250.0021
Post-Split Price
14 729.5745
Before
After
Dec 28, 2016
Dec 28, 2016
Split 1-for-1
/1
Pre-Split Price
14 525.7421 31 000.0017
Post-Split Price
14 793.3219
Before
After
Dec 29, 2015
Dec 29, 2015
Split 1-for-1
/1
Pre-Split Price
11 663.1915 28 150.0024
Post-Split Price
12 229.7377
Before
After
Dec 29, 2014
Dec 29, 2014
Split 1-for-1
/1
Pre-Split Price
7 815.638 21 300.0024
Post-Split Price
7 623.5426
Before
After
Dec 27, 2013
Dec 27, 2013
Split 1-for-1
/1
Pre-Split Price
5 163.2485 15 300.0021
Post-Split Price
5 283.8116
Before
After
Dec 27, 2012
Dec 27, 2012
Split 1-for-1
/1
Pre-Split Price
4 555.8075 14 700.0018
Post-Split Price
4 758.2878
Before
After
Dec 28, 2011
Dec 28, 2011
Split 1-for-1
/1
Pre-Split Price
N/A
Post-Split Price
3 409.1076
Before
After
Mar 28, 2008
Mar 28, 2008
Split 1-for-1
/1
Pre-Split Price
N/A
Post-Split Price
3 409.1076
Before
After
Mar 29, 2007
Mar 29, 2007
Split 1-for-1
/1
Pre-Split Price
N/A
Post-Split Price
3 409.1076
Before
After
Sep 24, 2004
Sep 24, 2004
Split 13199-for-11999
x1.1000083340278
Pre-Split Price
N/A
Post-Split Price
3 409.1076
Before
After
Apr 3, 2000
Apr 3, 2000
Split 21-for-20
x1.05
Pre-Split Price
N/A
Post-Split Price
3 409.1076
Before
After
Mar 30, 1999
Mar 30, 1999
Split 11-for-10
x1.1
Pre-Split Price
N/A
Post-Split Price
3 409.1076
Before
After
Jul 14, 1998
Jul 14, 1998
Split 10-for-1
x10
Pre-Split Price
N/A
Post-Split Price
3 409.1076
Before
After
Mar 30, 1998
Mar 30, 1998
Split 6-for-5
x1.2
Pre-Split Price
N/A
Post-Split Price
3 409.1076
Before
After
Mar 30, 1996
Mar 30, 1996
Split 81-for-77
x1.0519480519481
Pre-Split Price
N/A
Post-Split Price
3 409.1076
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 24, 2026
Cue Biopharma Inc
NASDAQ:CUE
CUE
Valuation & Fundamental Analysis Stock Splits Performance Benchmark
1-for-30
/30
0.5542 16.626 USD 17.695 17.695 USD
Apr 24, 2026
Medical Data Vision Co Ltd
TSE:3902
3902
Valuation & Fundamental Analysis Stock Splits Performance Benchmark
2-for-7253607
/3626803.5
1684 1684 JPY N/A
Apr 24, 2026
T
Trillion Energy International Inc
CNSX:TCF
TCF
Valuation & Fundamental Analysis Stock Splits Performance Benchmark
1-for-5
/5
0.2 0.2 CAD 0.18 0.18 CAD
Apr 24, 2026
E
ESGL Holdings Ltd
NASDAQ:ESGL
ESGL
Valuation & Fundamental Analysis Stock Splits Performance Benchmark
1-for-3
/3
2.35 7.05 USD 2.93 2.93 USD
Apr 24, 2026
Metro Mining Ltd
ASX:MMI
MMI
Valuation & Fundamental Analysis Stock Splits Performance Benchmark
1-for-20
/20
0.067 1.34 AUD 1.3 1.3 AUD
Load More

Bukwang Pharm Co Ltd
Glance View

Market Cap
755.7B KRW
Industry
Pharmaceuticals

Bukwang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The firm operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.

Intrinsic Value
2 178.11 KRW
Overvaluation 72%
Intrinsic Value
Price ₩7 660
What is Intrinsic Value?
Back to Top
ALPHA SPREAD
Follow us
Join more than 332,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett